Market Intelligence, Clinical Progress, and High-Purity Reagents for Targeted Protein Degradation and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RNF130 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Target Protein | RNF130 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View RNF130 Products |
| Gene Delivery | RNF130 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View RNF130 Products |
| Validator | RNF130 siRNA Set For knockdown verification. |
View RNF130 Products |
| Related Target A | VHL Synergistic E3 ligase network for PROTAC development. |
View VHL Products |
| Related Target B | CRBN Benchmark E3 ligase for targeted protein degradation assays. |
View CRBN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Structural Instability in E3 Ligases | Optimized recombinant expression with high purity (>95%) and strict theoretical MW verification. |
| Off-Target Ubiquitination | Sequence verified homolog panels available for precise counter-screening. |
| False Positives in Cell Assays | Validated siRNA included for strict specificity and knockdown checks. |
Live RNF130 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RNF130 therapeutics is intensifying, with major players shifting focus toward Targeted Protein Degradation (TPD) and novel small molecule PROTAC recruiters. As the limitations of traditional CRBN/VHL ligands become apparent, the next wave of R&D is heavily targeting emerging E3 ligases like RNF130 to bypass resistance and achieve tissue-specific degradation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / TPD | Leading Biotech & Pharma | Refractory Solid Tumors | Ternary Complex Formation (Need high-purity recombinant proteins) |
| Small Molecule Inhibitor | Early-stage Innovators | Immunology & Oncology | Selectivity Assay (Need structural integrity and purity) |
| Gene Therapy | Academic Consortia | Rare Genetic Disorders | Target Validation (Need Lentivirus for Stable Cell Lines) |